The United Kingdom sits between India and the United States on the spectrum of medical advertising freedom. British doctors are allowed to advertise their services — there is no blanket prohibition as there is in India — but the advertising is policed by several bodies at once, and one of the rules is not merely a professional standard but a criminal offence: it is illegal to advertise a prescription-only medicine to the public. That single rule, more than any other, defines how whole categories of UK healthcare — cosmetic injectables, weight-loss clinics, erectile-dysfunction services — are permitted to market themselves. This guide explains the whole framework and the recent enforcement that has made it bite.
01Who Regulates What
Four bodies matter most. The General Medical Council (GMC) sets the professional standards every doctor must meet, in Good Medical Practice and in dedicated guidance for doctors who offer cosmetic interventions; breaching them is a fitness-to-practise matter that can end in suspension or erasure from the register. The Advertising Standards Authority (ASA) enforces the CAP Code (non-broadcast advertising) and BCAP Code (broadcast), which require that ads be truthful, substantiated, and socially responsible. The MHRA (Medicines and Healthcare products Regulatory Agency) enforces the rules on advertising medicines, including the criminal ban on promoting prescription-only medicines to the public. And the CQC (in England; with separate regulators in Wales, Scotland, and Northern Ireland) registers and inspects providers carrying on regulated activities such as surgery. The CMA adds a consumer-protection overlay and, since April 2025, has direct power to fine for unfair commercial practices.
02What the GMC Requires of Every Doctor
The GMC's duties, drawn from Good Medical Practice (2024), are the baseline. Published information about your services must be factual and verifiable, and not false or misleading. You must not make unjustifiable claims about the quality of your services. You must not offer guarantees of cures, nor claim or imply that an intervention is risk-free. You must not exploit patients' vulnerability or lack of medical knowledge, and you must not put pressure on people to use a service by playing on their fears or dangling inducements. And you must be honest and open about any financial or commercial interests when you promote or endorse a product or service.
For cosmetic interventions the GMC goes further. You must market responsibly, must not trivialise the risks, and — importantly — must not use promotional tactics that could push someone into an ill-considered decision. That explicitly includes time-limited financial offers ("today only") and two-for-one or package deals, which are treated as pressure selling for irreversible procedures.
03The Rule That Changes Everything: No Advertising POMs to the Public
Here is the rule that catches the most practices and is the most serious, because it is criminal. Under the CAP Code (rule 12.12) and, behind it, the Human Medicines Regulations 2012, prescription-only medicines may not be advertised to the public at all. You also may not use a health professional or celebrity to endorse a medicine.
The crucial subtlety is how broadly "advertising a POM" is read. The ASA's working principle is that any reference to a prescription-only medicine is likely to amount to promoting it. That sweeps in not just brand names (Botox, Dysport; Ozempic, Wegovy, Mounjaro) but the proxies people reach for to get around the brand: "anti-wrinkle injections," "wrinkle relaxers," "#brotox," "weight-loss injections," "skinny jab," "weight-loss pen," "GLP-1," and even describing the condition the drug treats as a route to selling it. Imagery counts too — syringes, vials, injection pens, and before-and-after photos are all treated as promotion.
The permitted approach is a narrow one the ASA sums up as "promote the consultation, not the POM." A clinic may advertise a consultation ("a consultation about lines and wrinkles," "a weight-management consultation") without naming or depicting the prescription medicine. A clinic's own website may give purely factual information about a POM only in a narrow, non-promotional way reached after a consultation page — never on the homepage, never in an ad, never with testimonials or promotional language.
This is not theoretical. CAP issued a formal enforcement notice on Botox advertising on social media, the ASA has ruled against influencers promoting it, and in September 2025 the ASA, MHRA, and the pharmacy regulator issued a joint enforcement notice to all registered pharmacies over weight-loss medicine advertising, with monitoring of tens of thousands of ads and formal action against multiple advertisers. The ASA now uses AI to scan social media for these breaches at scale.
04Cosmetic Procedures: The Tightest Rules
Beyond the POM ban, cosmetic advertising carries extra constraints. Botulinum toxin advertising to the public is effectively banned across paid ads, organic posts, and influencer content alike. Before-and-after imagery for non-POM treatments may only be used with signed, dated proof that the images are genuine and unaltered — no filters, no retouching of the "after" image — and a disclaimer cannot rescue misleading imagery. Ads for non-surgical cosmetic procedures must not target under-18s. And separately from advertising law, it is a criminal offence under the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021 to administer botulinum toxin or fillers to under-18s for cosmetic purposes at all, carrying an unlimited fine. A government-confirmed licensing scheme for non-surgical cosmetic procedures in England is coming but, as of writing, is not yet in force.
05The Penalties
The GMC can issue warnings, impose conditions, suspend a doctor for up to a year at a time, or erase them from the register entirely. The ASA cannot fine for most ads, but it publishes adverse rulings, orders ads withdrawn, has them removed from paid search and social platforms, names persistent offenders, and refers serious cases to legal backstops — Trading Standards, the CMA, or the MHRA. The MHRA route is the sharp one: advertising a prescription-only medicine to the public is a criminal offence carrying, on the figures commonly cited, an unlimited fine and potential imprisonment. The CMA, since the Digital Markets, Competition and Consumers Act came into force in April 2025, can directly impose substantial fines for misleading practices. And operating a regulated activity without CQC registration is itself a criminal offence.
06A Compliant UK Marketing Playbook
Build your marketing on factual, verifiable information about your services, qualifications, and genuine pricing. For anything involving a prescription-only medicine, sell the consultation and never the drug — no brand names, no proxies, no syringe imagery, no before-and-afters, in any channel including organic and influencer posts. Drop time-limited offers and package deals for cosmetic procedures. If you use testimonials for non-POM services, keep documentary proof they are genuine, and never use them to reference a POM. Educate rather than pressure — accurate, responsible content about conditions and options is both what the GMC wants and what builds durable trust. And if you are in England and carry on a regulated activity, make sure you are CQC registered before you advertise it.
This is general educational information, not legal advice. UK medical advertising law spans the GMC, ASA/CAP, MHRA, CMA, and CQC, several rules are mid-reform, and devolved nations differ. Confirm the current position with a qualified UK healthcare or advertising lawyer and the relevant regulator before acting.
